Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 exon 14 ins |
Therapy | Dubermatinib + Sorafenib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Dubermatinib + Sorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Dubermatinib (TP-0903) and Nexavar (sorafenib) inhibited proliferation of an acute myeloid leukemia cell line harboring a FLT3-ITD in culture (PMID: 39395205). | 39395205 |
PubMed Id | Reference Title | Details |
---|---|---|
(39395205) | Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia. | Full reference... |